Lafutidine-based triple therapy for Helicobacter pylori eradication

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1074-1081

  Ren, Qian ^a   Bin, Ma ^a   Yang, Kehu ^a   Yan, Xiang ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Eradication; Helicobacter pylori; Lafutidine; Meta analysis; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FAMOTIDINE; LAFUTIDINE; LANSOPRAZOLE;

ARTICLE; COCHRANE LIBRARY; CONSTIPATION; DATA BASE; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; EMBASE; EPIGASTRIC DISCOMFORT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEDLINE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SORE THROAT; STOMACH ULCER; STOMATITIS; SYMPTOM; TASTE DISORDER; TREATMENT RESPONSE; VOMITING;

ACETAMIDES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; PIPERIDINES; PYRIDINES;

EID: 79251540580     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Go MF: Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16 Suppl 1:3-15.
2. Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002; 347:1175-1186.
3. Graham DY, Lew GM, Evans DG, Evans DJ Jr, Klein PD: Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991; 115:266-269.
4. Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244-1252.
5. Tytgat GN: Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8:359-368.
6. Kim N, Lim SH, Lee KH, Jung HC, Song IS, Kim CY: Helicobacter pylori reinfection rate and duodenal ulcer recurrence in Korea. J Clin Gastroenterol 1998; 27:321-326.
7. Asaka M, Sugiyama T, Kato M, Satoh K, et al: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6:254-261.
8. Shirin H, Birkenfeld S, Shevah O, Levine A, et al: Application of Maastricht 2-2000 guidelines for the management of Helicobacter pylori among specialists and primary care physicians in israel: are we missing the malignant potential of Helicobacter pylori. J Clin Gastroenterol 2004; 38:322-325. (Pubitemid 38393067)
9. Della MP, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A: Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16:1269-1275.
10. Hunt RH, Fallone CA, Thomson AB: Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol 1999; 13:213-217.
11. Sakaguchi M, Ashida K, Umegaki E, Miyoshi H, Katsu K: Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. J Clin Gastroenterol 1995; 20 Suppl 2:S27-31.
12. Ell C, Schoerner C, Solbach W, Stolte M, Vieth M, Ridl W, Moser W: The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2001; 13:685-691.
13. Graham DY, Hammoud F, El-Zimaity HM, Kim JG, Osato MS, El-Serag HB: Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17:1229-1236.
14. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM: Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 18:757-766.
15. Yamaura T, Shibata M, Inaba N, Onodera S, Chida Y, Ohnishi H: Effects of FRG-8813, a new type histamine H2-receptor antagonist, on various experimental gastric and duodenal lesions in rats. Nippon Yakurigaku Zasshi 1992; 99:401-410. (In Japanese with English abstract).
16. Yamaura T, Shibata M, Chida Y, Inaba N, Onodera S, Ohnishi H: Effects of FRG-8813, a new-type histamine H2-receptor antagonist, on the healing of gastric and duodenal ulcer in rats and spontaneously ulcerative mice]. Nippon Yakurigaku Zasshi 1992; 99:411-420. (In Japanese with English abstract).
17. Shibata M, Yamaura T, Inaba N, Onodera S, Chida Y, Ohnishi H: Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. Eur J Pharmacol 1993; 235:245-253.
18. Fukushima Y, Otsuka H, Ishikawa M, et al: Potent and long-lasting action of lafutidine on the human histamine H(2) receptor. Digestion 2001; 64:155-160.
19. Scarpignato C, Pelosini I, Di MF: Acid suppression therapy: where do we go from here. Dig Dis 2006; 24:11-46.
20. Onodera S, Shibata M, Tanaka M, Inaba N, Arai Y, Aoyama M, Lee B, Yamaura T: Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity. Arzneimittelforschung 1999; 49:519-526.
21. Ichikawa T, Ota H, Sugiyama A, Maruta F, Ikezawa T, Hotta K, Ishihara K: Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa. J Gastroenterol Hepatol 2007; 22:1800-1805. (Pubitemid 47525074)
22. Ajioka H, Miyake H, Matsuura N: Effect of FRG-8813, a new-type histamine H(2)-receptor antagonist, on the recurrence of gastric ulcer after healing by drug treatment in rats. Pharmacology 2000; 61:83-90.
23. Onodera S, Tanaka M, Aoyama M, Arai Y, et al: Anti-ulcer effect of lafutidine on indomethacin-induced gastric antral ulcers in refed rats. Jpn J Pharmacol 1999; 80:229-235.
24. Yamagishi H, Koike T, Ohara S, Horii T, Kikuchi R, et al: Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole. World J Gastroenterol 2008; 14:2406-2410.
25. Isomoto H, Inoue K, Furusu H, Nishiyama H, et al: Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 2003; 8:111-119.
26. Hagiwara T, Kato M, Anbo T, Imamura A, Suga T, et al: Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. World J Gastroenterol 2007; 13:3836-3840.
27. Kim N, Park SH, Seo GS, Lee SW, Kim JW, et al: Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008; 13:542-549.
28. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.
29. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
30. Adachi K, Katsube T, Kawamura A, Takashima T, et al: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14:1259-1266.
31. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M: Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther 2003; 18:1149-1157. (Pubitemid 38021601)
32. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G: Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008; 13:532-541.
33. Higuchi K, Watanabe T, Tominaga K, Shiba M, et al: Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial. Inflammopharmacology 2006; 14:226-230.